Nonetheless, low-dose IL-2 is currently included in a number of clinical trials to support cellular adoptive approaches with combined infusions of NK cells and trastuzumab in HER2+ breast cancer patients (NCT02030561, NCT02843126). Here, IL2 is linked to breast cancer.